Shingrix Vaccine Now FDA Approved for All Immunocompromised Adults

The U.S. Food and Drug Administration (FDA) has approved the Shingrix vaccine, which prevents shingles, for all adults aged 18 and older who have increased risk of immunodeficiency or immunosuppression.¹

The two-dose vaccine was originally approved by the FDA in 2017 to prevent shingles in adults aged 50 and older. The new approval significantly expands the pool of patients eligible for the vaccine.

In addition to older age, being immunocompromised is one of the greatest risk factors for contracting shingles, according to an official with GlaxoSmithKline (GSK), which makes the vaccine. While spondyloarthritis (SpA) itself does not make a person immunocompromised, certain medications used to treat SpA may suppress the immune system.

If you are interested in, and think you might be eligible for the Shingrix vaccine, speak to your doctor about its appropriateness.

1. FDA Approves Shingrix Vaccine for Immunocompromised Patients (hcplive.com)